Patents by Inventor Michael Sasner

Michael Sasner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetically modified mouse expressing human APOE4 and mouse Trem2 p.R47H and methods of use thereof
    Patent number: 11957115
    Abstract: Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p,R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods ace provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: April 16, 2024
    Assignees: The Jackson Laboratory, Indiana University Research and Technology Corporation
    Inventors: Gareth Howell, Michael Sasner, Gregory Carter, Bruce Lamb
  • GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER'S DISEASE
    Publication number: 20210195879
    Abstract: The present disclosure provides a genetically modified mouse comprising a genomic nucleic acid encoding human APOE4, a genomic nucleic acid encoding mouse TREM2 modified to include a R47H substitution, and at least one genomic modification selected from the group consisting of: (a) a genomic nucleic acid encoding mouse ABCA7 modified to include an A 1541 G substitution; (b) a genomic nucleic acid encoding mouse APP modified to include G601R, F606Y, and R609H substitutions; (c) a genomic nucleic acid encoding mouse PLCG2 modified to include a M28L substitution; (d) a genomic nucleic acid encoding mouse MTHFR modified to include a A262V substitution; (e) an inactivated Ceacam1 allele; and (f) an inactivated Il1rap allele. Methods of producing the genetically modified mouse and methods of using the genetically modified mouse are also provided.
    Type: Application
    Filed: June 21, 2019
    Publication date: July 1, 2021
    Applicants: The Jackson Laboratory, Indiana University Research and Technology Corporation, Sage Bionetworks
    Inventors: Gareth Howell, Gregory Carter, Michael Sasner, Stacey Rizzo, Harriet Williams, Bruce Lamb, Paul Territo, Adrian Oblak, Ben Logsdon, Lara Mangravite, Leah Graham
  • A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE TREM2 P.R47H AND METHODS OF USE THEREOF
    Publication number: 20200022343
    Abstract: Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p,R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods ace provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.
    Type: Application
    Filed: March 21, 2018
    Publication date: January 23, 2020
    Applicants: The Jackson Laboratory, Indiana University Research and Technology Corporation
    Inventors: Gareth Howell, Michael Sasner, Gregory Carter, Bruce Lamb